[1] 贾国华,陈亚红. 2017年西班牙慢性阻塞性肺疾病指南解读[J].中国医学前沿杂志(电子版),2017,9(12):23-27. [2] Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary[J].Respirology,2017,22(3):575-601. [3] Toraldo DM, Conte L. Influence of the lung microbiota dysbiosis in chronic obstructive pulmonary disease exacerbations: the controversial use of corticosteroid and antibiotic treatments and the role of eosinophils as a disease marker[J].J Clin Med Res,2019,11(10):667-675. [4] 周薇,彭红星. 老年慢性阻塞性肺疾病病人呼出气一氧化氮水平的变化及临床意义[J].实用老年医学,2019,33(3):237-240. [5] Lu ZY, Huang WN, Wang LF, et al. exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis[J].Int J Chron Obstruct Pulmon Dis,2018,13: 2695-2705. [6] Andras B, Martina M, Zsofia L. Exhaled nitric oxide in COPD[J].Curr Respirat Med Rev,2019,15(2):71-78. [7] Yang X, Huo B, Zhong XN, et al. Imbalance between subpopulations of regulatory t cells in patients with acute exacerbation of COPD[J].COPD,2017,14(6): 618-625. [8] Weiszhar Z, Horvath I. Induced sputum analysis: step by step[J].Breathe,2013,9(4):300-306. [9] Jafarinejad H, Moghoofei M, Mostafaei S, et al. Worldwide prevalence of viral infection in AECOPD patients: A meta-analysis[J].Microb Pathogl,2017,113:190-196. [10] Britto CJ, Brady V, Lee S, et al. Respiratory viral infections in chronic lung diseases[J].Clin Chest Med,2017,38(1):87-96. [11] 付立娜,王珺,蔡成森,等. 嗜酸粒细胞与慢性阻塞性肺疾病患者激素治疗及预后关系的研究进展[J].实用心脑肺血管病杂志, 2019,27(6):5-7. [12] 中华医学会呼吸病学分会哮喘学组. 咳嗽的诊断与治疗指南(2015) [J].中华结核和呼吸杂志, 2016,39(5):323-354. [13] Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load[J].Respir Res,2017,18(1):88. [14] Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations [J].Am J Respir Crit Care Med,2006,173(10):1114-1121.
2020, Vol. 37 
